Partial
Mostly Aligned
Patient Risk:
Info
Summary
Indications are supported by the provided label excerpts. Multiple safety/adverse-event percentage claims are not verifiable because the provided label excerpts do not include the specific incidence rates or the listed symptoms with those exact percentages.
Category Scores
Accurate Statements
Taltz (ixekizumab) is used to treat psoriatic arthritis.
Label excerpt 1.2 Psoriatic Arthritis: TALTZ indicated for adult patients with active psoriatic arthritis.
Taltz (ixekizumab) is used to treat plaque psoriasis.
Label excerpt 1.1 Plaque Psoriasis: indicated for patients 6 years of age and older with moderate-to-severe plaque psoriasis.
Increased risk of infections (bacterial, viral, or fungal infections) was reported in up to 2% of patients receiving Taltz.
Label excerpt 5.1 Infections: TALTZ may increase the risk of infection; postmarketing serious bacterial, viral, and fungal opportunistic infections have been reported. (Incidence rate 'up to 2%' not present in provided excerpts.)
Unsupported Statements
Nausea occurred in 34% of patients receiving Taltz.
The provided label excerpts (Section 6 adverse reactions excerpt) do not list nausea incidence percentages.
Nausea led to vomiting in 3% of patients receiving Taltz.
The provided label excerpts do not provide rates for nausea or vomiting, nor a statement linking them.
Injection site reactions (such as redness or itching) occurred in up to 15% of patients receiving Taltz.
The provided label excerpts do not include incidence rates for injection site reactions or their specific sub-features.
Headache was reported in up to 14% of patients receiving Taltz.
The provided label excerpts do not provide headache incidence percentages.
Diarrhea was experienced by up to 13% of patients receiving Taltz.
The provided label excerpts do not provide diarrhea incidence percentages.
Allergic reactions, which can be life-threatening, occurred in less than 1% of patients receiving Taltz.
Label excerpt 5.3 indicates serious hypersensitivity including angioedema and urticaria each ≤0.1% and anaphylaxis has been reported in postmarketing use; the provided excerpts do not support a combined 'allergic reactions' frequency of 'less than 1%'.
Increased risk of infections (bacterial, viral, or fungal infections) was reported in up to 2% of patients receiving Taltz.
While infections are discussed, the provided excerpts do not include an incidence rate of 'up to 2%'.
Low blood platelet count (thrombocytopenia) occurred in less than 1% of patients receiving Taltz.
The provided label excerpts do not mention thrombocytopenia or an incidence rate.
Anaphylaxis occurred as a rare potentially severe side effect in patients taking Taltz.
The provided label excerpts state that anaphylaxis has been reported in postmarketing use, but they do not include the 'rare' characterization.
Angioedema occurred as a rare potentially severe side effect in patients taking Taltz.
The provided label excerpts state angioedema occurred each ≤0.1% in clinical trials, but do not characterize it as 'rare'.
Stevens-Johnson syndrome occurred as a rare but serious side effect in patients taking Taltz.
The provided label excerpts do not mention Stevens-Johnson syndrome.
Contradictions
Important Omissions
For infection risk statements: the label excerpt specifies TB evaluation prior to initiation and that initiation is not recommended in active TB; the AI claims did not address TB evaluation.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Info
Several adverse event percentage statements (nausea/vomiting, injection site reactions, headache, diarrhea, thrombocytopenia, J-S syndrome, and characterization as 'rare') are not supported by the provided label excerpts, reducing label fidelity. The indications are supported.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Medium |
Recommendation
Mostly Aligned
Primary Issue
Adverse reaction claims include specific incidence rates and severities that are not present in the provided prescribing-information excerpts.
Suggested Improvement
Remove or qualify all adverse-event frequency and 'rare' characterizations unless the exact percentages/severity categories are supported by the provided label sections; limit safety claims to those explicitly stated in the excerpts (e.g., infection risk generally; hypersensitivity including angioedema ≤0.1% and anaphylaxis reported postmarketing).